Title: How do venture capitalists spread risk by diversification within specialised life science portfolios?

Authors: Holger Patzelt, Dodo Zu Knyphausen-Aufseß, Ilona Arnoldt

Addresses: Max-Planck-Institute of Economics Entrepreneurship, Growth and Public Policy Group, Kahlaische Str. 10, 07745 Jena, Germany. ' Otto-Friedrich-University of Bamberg, Feldkirchenstr. 21, D-96045 Bamberg, Germany. ' University of Bamberg, Feldkirchenstr. 21, D-96045 Bamberg, Germany

Abstract: Venture Capitalists (VC) invest large amounts of money in risky start-up firms. In order to keep their investment risks low, they carefully select their portfolio companies and systematically spread risks portfolio companies are well studied, little is known about how VCs diversify their portfolios, in particular when dedicated to one industry. We introduce a framework for analysis of dedicated life science portfolios. By applying it to seven portfolios and drawing on additional interview data, we find that VCs invest more in risky drug development companies and less in medical technology, diagnostics and service/supply firms when their portfolio also contains non-life science firms. A higher portion of drug development firms correlate with more diversification within this sub-portfolio among different therapeutic markets and lead compound technologies. We conclude that specialisation within one industry on certain technologies or markets does not contribute to VCs| risk reduction.

Keywords: venture capital; biotechnology; portfolio strategy; portfolio diversification; risk; specialisation; multiple case study; life sciences.

DOI: 10.1504/IJTM.2006.009450

International Journal of Technology Management, 2006 Vol.34 No.1/2, pp.105 - 125

Published online: 03 Apr 2006 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article